|
|
Volumn 332, Issue 6027, 2011, Pages 297-
|
|
Frightening risk of marfan syndrome, and potential treatment, elucidated
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
LOSARTAN;
MITOGEN ACTIVATED PROTEIN KINASE;
SMAD PROTEIN;
TRANSFORMING GROWTH FACTOR BETA;
PROTEIN KINASE INHIBITOR;
AORTA ANEURYSM;
ENZYME INHIBITION;
GENOMICS;
HUMAN;
MARFAN SYNDROME;
NONHUMAN;
NOONAN SYNDROME;
NOTE;
PRIORITY JOURNAL;
RISK FACTOR;
SIGNAL TRANSDUCTION;
ANIMAL;
CLINICAL TRIAL (TOPIC);
DRUG ANTAGONISM;
METABOLISM;
MOUSE;
ANIMALS;
AORTIC ANEURYSM;
CLINICAL TRIALS AS TOPIC;
EXTRACELLULAR SIGNAL-REGULATED MAP KINASES;
HUMANS;
LOSARTAN;
MAP KINASE SIGNALING SYSTEM;
MARFAN SYNDROME;
MICE;
PROTEIN KINASE INHIBITORS;
SIGNAL TRANSDUCTION;
TRANSFORMING GROWTH FACTOR BETA;
|
|
EID: 79954621563
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.332.6027.297 Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|
